Market revenue in 2023 | USD 442.6 million |
Market revenue in 2030 | USD 599.1 million |
Growth rate | 4.4% (CAGR from 2023 to 2030) |
Largest segment | Cardiopulmonary perfusion system |
Fastest growing segment | Cardiopulmonary Perfusion System |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cardiopulmonary Perfusion System, Cell Perfusion System, Ex-Vivo Organ Perfusion System |
Key market players worldwide | Getinge AB ADR, Medtronic PLC, LivaNova PLC, Terumo Corp, Nipro Corp, Fresenius Medical Care AG, Repligen Corp, Spectrum Brands Holdings Inc, Merck KGaA, Xvivo Perfusion AB |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to perfusion systems market will help companies and investors design strategic landscapes.
Cardiopulmonary perfusion system was the largest segment with a revenue share of 44.74% in 2023. Horizon Databook has segmented the North America perfusion systems market based on cardiopulmonary perfusion system, cell perfusion system, ex-vivo organ perfusion system covering the revenue growth of each sub-segment from 2018 to 2030.
In 2023, North America dominated the global perfusion systems market. The dominance can be attributed to the well-established healthcare sector, commitment to innovation, advanced infrastructure, a strong emphasis on R&D, and the high prevalence of respiratory and cardiac disorders. North America faces a significant burden of cardiovascular and respiratory diseases, leading to a rising demand for perfusion systems used in surgeries for these conditions.
The growing number of organ transplants necessitates advanced perfusion systems for organ preservation and viability during the transplant process. Continuous development of perfusion systems with improved functionalities, like Normothermic Machine Perfusion (NMP), fuels market growth.
In January 2024, Penn Medicine announced a significant advancement in liver transplantation with the first successful use of an external perfusion system incorporating a genetically modified pig liver. This technology holds promise as a bridge for patients on the waiting list for organ transplants. The researchers conducted a successful experiment on external liver perfusion.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America perfusion systems market , including forecasts for subscribers. This continent databook contains high-level insights into North America perfusion systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account